Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
8.60 p
0.00 p(0.00%)
At close: 4:00 PM EDT
8.60 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range3.30 p - 9.30 p
Previous CloseN/A
Volume885.20K
Average Volume (3M)2.14M
Market Cap
£47.71M
Enterprise Value43.38M
Total Cash (Recent Filing)£4.82M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding763,437,130
10 Day Avg. Volume1,193,520
30 Day Avg. Volume2,135,786
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt limits leverage-related pressure and preserves flexibility while the company advances clinical programs. A low-debt structure can reduce mandatory cash obligations and provide greater scope to direct available funds toward development, partnerships, and evidence generation.
Regulatory And IP ProgressMHRA approval, an operational trial network, and long-dated patent protection show meaningful execution progress around POLB 001. These milestones reduce development friction, support defensibility, and improve the asset’s potential attractiveness to licensing or co-development partners.
Strong Target-engagement SignalDose-dependent suppression of IL-6 and IL-8, reaching approximately 85%–95% at higher doses, provides a substantive pharmacodynamic signal. Demonstrated target engagement can support clinical translation, strengthen partnering discussions, and improve the rationale for advancing the program.
Bears Say
Pre-revenue Loss ProfileThe company has no commercial revenue to offset continuing R&D and operating expenses, while annual losses remain material. Until a program is partnered or commercialized, earnings depend on advancing unproven assets and securing funding rather than recurring operating income.
Persistent Cash BurnSustained negative operating cash flow shows that ongoing development consumes substantial resources without internally generated funding. Continued burn increases dependence on financing, grants, or licensing proceeds and can constrain the pace and scale of future clinical execution.
Limited Trial ConclusivenessThe small, open-label, single-arm design may identify an initial efficacy signal but cannot provide the same evidentiary strength as a controlled study. Further trials could therefore be needed, extending timelines, increasing costs, and delaying partnering or commercialization decisions.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 3.30 p and its highest was 9.30 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £47.71M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 133 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Sep 29, 2026. The company reported -0.003 p earnings per share for the quarter.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.003 p in its last earnings report. Following the earnings report the stock price went up 0.68%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.57%
12-Months-Change
Fundamentals
Return on Equity
-71.28%
Trailing 12-Months
Asset Growth
-42.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―